Kaplan Fox & Kilsheimer LLP Encourages Flotek Industries, Inc. (NYSE: FTK) Investors to Contact the Firm Before October 26, 2026

A securities class action has been filed against Flotek Industries over allegations that its 10-year PREPA contract, representing approximately $400 million and 57% of backlog, was canceled. Following Wolfpack Research's August 17 report alleging the cancellation, FTK shares fell $7.17, or 20%, to $28.66. The complaint alleges Flotek failed to disclose concerns over the PREPA consortium's experience and financial capacity, creating risk that contract revenue would not be realized.

Analysis

This is not a new fundamental disclosure; it is a plaintiff-lawyer solicitation that extends the news cycle around a pre-existing short-seller allegation. The investable issue is whether FTK can replace a potentially concentrated backlog source without impairing utilization, working capital, and forward gross-margin expectations. If the disputed project was embedded in management’s revenue or EBITDA outlook, the likely next leg lower comes from guidance revision rather than litigation damages, which are typically immaterial to near-term enterprise value relative to contract economics.

Near term, FTK faces an adverse-information asymmetry: management must produce independently verifiable evidence of counterparty financing, project authorization, scope, and cancellation status, while the market will discount generic denials. A 1-3 month catalyst path includes contract documentation, PREPA/consortium confirmation, quarterly backlog reconciliation, and any change in revenue guidance. Over 6-18 months, a lost or delayed project would also raise customer-concentration and governance discounts, potentially compressing FTK's valuation versus better-diversified production-chemicals peers; the relevant risk is not only foregone revenue but lower credibility assigned to future awarded backlog.

The contrarian case is that the market has already priced a cancellation probability materially above reality following the sharp selloff, while the lawsuit itself adds no new evidence. A verified, enforceable contract with funded counterparties could trigger a violent short-covering rally given likely elevated borrow demand. BAC and ALV have no apparent operational linkage to this thesis and should not be traded off this item.

Key Decisions for Investors

• Maintain a bearish FTK bias but do not chase the post-report move. Initiate a small short only on a relief rally that fails below the pre-allegation trading range, or after a quarterly backlog/guidance revision confirms revenue impairment; target 20-30% downside over 1-3 months, with a hard stop on documentary confirmation of project funding and enforceable scope.
• For defined risk, prefer FTK put spreads expiring after the next earnings release rather than outright puts: buy an at/near-money put and sell a 20-25% lower-strike put. This captures a guidance-reset scenario while limiting premium exposure if management substantiates the contract.
• Set diligence alerts for PREPA procurement records, consortium financing commitments, FTK's reported backlog bridge, and any revised full-year revenue/EBITDA guidance. Treat an unchanged outlook supported by third-party documentation as thesis falsification; treat omission of the project from backlog disclosures as escalation.
• Avoid using the class-action filing as a standalone catalyst. Securities litigation can persist for years and is generally not a reliable driver of near-term cash costs or valuation absent evidence of regulatory action, insurance-limit issues, or management departures.